---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-008193"
form_type: "8-K"
ticker: "ACTU"
cik: "0001652935"
company_name: "ACTUATE THERAPEUTICS, INC."
filed_at: "2026-10-30T20:05:24+00:00"
generated_at: "2026-10-30T20:06:07.091555+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Actuate Therapeutics gets Nasdaq minimum bid price notice; 180 days to April 26, 2027 to regain $1.00

## Summary
- Nasdaq notice dated Oct 28, 2026: ACTU closing bid stayed below $1.00 for 30 consecutive business days, breaching Rule 5450(a)(1).
- Compliance window runs 180 calendar days to April 26, 2027; requires 10 straight closes at $1.00 or more plus meeting other Global Market standards.
- Common stock continues trading on the Nasdaq Global Market under ACTU; the notice has no immediate effect on listing.
- Separate July 15, 2026 MVLS deficiency notice gives until January 11, 2027; a second 180-day bid-price period would require moving to the Nasdaq Capital Market.
- Company says it is monitoring its bid price and weighing options, with no assurance it regains compliance or avoids delisting.

## SEC filing metadata
- accession: 0001683168-26-008193
- form_type: 8-K
- ticker: ACTU
- cik: 0001652935
- company_name: ACTUATE THERAPEUTICS, INC.
- filed_at: 2026-10-30T20:05:24+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652935/000168316826008193/0001683168-26-008193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652935/000168316826008193/actuate_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-008193
- JSON: https://secwatch.observer/filing/0001683168-26-008193.json
- Plain text: https://secwatch.observer/filing/0001683168-26-008193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.